CGA also increases the expression levels of genes involved in fatty acid metabolism, including Cpt1a, Cpt1b, and Fgf21, while decreasing the expression levels of Pparγ1, Pparγ2, and their target genes Cd36, Fabp4, and Mgat1, thereby ameliorating hepatic steatosis and insulin resistance [38]. The gene discussed is CPT1A; the disease is Hepatic steatosis.